China's Innovent clinches new Lilly deal for immunology, cancer drug development
I'm PortAI, I can summarize articles.
China’s Innovent Biologics has secured a new deal with Eli Lilly for the development of immunology and oncology drugs, involving an upfront payment of $350 million and potential additional payments of up to $8.5 billion based on milestones. Innovent will lead the development in China, while Lilly will have exclusive rights to commercialize the products outside Greater China. This partnership marks their seventh collaboration and aims to create a comprehensive innovation ecosystem, enhancing Innovent's R&D capabilities.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments